Office: VA, Bldg. # 2, Room 109
Phone: (423) 439-6289 Office
Phone: (423) 895-0229 Cell
Jim L. Kelley, Ph.D. is Professor, Department of Internal Medicine at the Quillen College of Medicine, East Tennessee State University, Johnson City, TN. He received a Ph.D. from the University of Oklahoma in 1973 in Biochemistry and Molecular Biology. He received post-graduate training at the Oklahoma Medical Research Foundation under the supervision of Dr. Petar Alaupovic, an Internationally recognized expert in lipoprotein research. In 1981 Dr. Kelley took a faculty position at the University of Texas Health Sciences Center in San Antonio, TX where he worked closely with Dr. Henry McGill and Dr. Colin Schwartz, both of whom are nationally and internationally know researchers in the field of experimental atherosclerosis. In 1994, Dr. Kelley took a faculty position at the Quillen College of Medicine in the Department of Surgery and after two years joined the Department of Internal Medicine where he moved up in the ranks to tenured Professor.
Dr. Kelley has a long history of publication in the area of cardiovascular disease focusing on various aspects of atherosclerosis, lipoprotein metabolism, macrophage biology and the role of scavenger receptor A in atherosclerosis, sepsis, ischemia reperfusion injury in brain and heart and other inflammatory diseases. To date he lists 86 peer reviewed manuscripts in top-tier journals along with an equal number of abstracts and presentations. Dr. Kelley has been funded by the National Institutes of Health (NIH) most of his career as PI, Co-PI, Co-I, collaborating investigator and consultant.
Dr. Kelley has made a number of important contributions to the unraveling of mechanisms of atherogenesis. His work established the central role of monocyte derived macrophage in the development of the "foam" cell using the carrageenan granuloma model which has since been used by many investigators interested in the cell biology of the development of atherosclerotic lesions. He established that both naïve and chemically modified serum lipoproteins activate monocyte derived macrophages and leads to an inflammatory state. Dr. Kelley and colleagues were the first to describe the chemoattraction of monocytes to the atherosclerotic artery. While the term monocyte chemotactic protein-1 (MCP-1) is a household name today, Dr. Kelley described the generation of a monocyte chemoattracting protein from atherosclerotic arteries in 1984. Dr. Kelley pioneered research on the characterization of the acetyl low density lipoprotein (AcLDL) receptor of macrophage foam cells. While the scavenger receptor concept has been expanded enormously in recent years and everyone takes credit for it, Dr. Kelley was the one who first described the identification and purification of a large molecular weight, trimeric protein that was responsible for the binding and uptake of Acetylated and oxidized LDL. This protein is now designated as scavenger receptor A. His continued studies of SR-A functions have led to the discoveries that SR-A plays important roles not only in atherosclerosis, but in in other diseases where inflammation is a component, including sepsis, endotoxemia, and ischemia/reperfusion injury in both brain and heart.
One of Dr. Kelley's strengths is his capacity to develop long-lasting collaborations. In these days of explosion of scientific knowledge, he realized that the best way to succeed in biomedical research is to seek out colleagues having similar research interests, but complementary talents.
Dr. Kelley has been an active participant in the NIH peer review system, having served eight years on the study section reviewing SBIR/STTR proposals relating to drug discovery and chaired two of the sessions. He is known by other reviewers for his breadth of knowledge, his wit, and fair evaluation of complex proposals. He has a talent for analyzing complex and varied data, summarizing it, and providing a comprehensive analysis of proposals, then presenting them in a clear way such that the committee could arrive at fair and reasonable conclusions. He also served on numerous ad hoc study sections for the National Heart Lung and Blood Institute (NHLBI) and most recently on the study section reviewing proposals for the National Center for Complementary and Alternative Medicine (NCCAM). Dr. Kelley is a member of the American Heart Association (AHA) and formerly a Fellow of the American Heart Association (FAHA). He is also a fellow of the International Atherosclerosis Society (IAS) and has been a member of numerous other professional and scientific societies.
Dr. Kelley serves on numerous committees at the University, College and Department levels. Of note, he served from 1998-2012 as an elected representative of the College of Medicine to the ETSU faculty senate.
While research is Dr. Kelley's main focus, in recent years he has taught in the College of Medicine's Case Oriented Learning (COL) class for first year medical students that he found to be very rewarding.
B.S., Southern Nazarene University, Chemistry, Bethany, Oklahoma, 1965-1969
Ph.D., University of Oklahoma, Biochemistry, Norman, Oklahoma, 1969-1973
-Post-doctoral Fellow, Oklahoma Medical Research Foundation, Oklahoma City, OK, 1973-1976
-Visiting Assistant Professor, Department of Pathology, The University of Texas Health Science Center, San Antonio, TX, 1979-1980
Special Areas of Interest:
atherosclerosis, heart disease; inflammation and cytokines; ma crophage scavenger receptors; intracellular signaling